Descartes-08
Generalized Myasthenia Gravis (gMG)
Key Facts
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company with a mission to expand the reach of cell therapy beyond oncology into autoimmune diseases. The company's core innovation is an mRNA cell therapy platform designed to transiently engineer patient-derived cells to produce therapeutic proteins locally at disease sites, aiming for a favorable safety and efficacy profile. Its strategy is validated by a maturing clinical pipeline, led by Descartes-08 in Phase 2b for generalized myasthenia gravis, positioning it as a public leader in this emerging therapeutic modality. Cartesian faces significant execution risks but operates in a vast and underserved market with a potentially disruptive technology.
View full company profileAbout Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company with a mission to expand the reach of cell therapy beyond oncology into autoimmune diseases. The company's core innovation is an mRNA cell therapy platform designed to transiently engineer patient-derived cells to produce therapeutic proteins locally at disease sites, aiming for a favorable safety and efficacy profile. Its strategy is validated by a maturing clinical pipeline, led by Descartes-08 in Phase 2b for generalized myasthenia gravis, positioning it as a public leader in this emerging therapeutic modality. Cartesian faces significant execution risks but operates in a vast and underserved market with a potentially disruptive technology.
View full company profileTherapeutic Areas
Other Generalized Myasthenia Gravis (gMG) Drugs
| Drug | Company | Phase |
|---|---|---|
| ignaseclant (NMD670) | NMD Pharma | Phase 2 |
| Efgartigimod (VYVGART) | Argenx | Approved |
| Anitocabtagene Autoleucel (anito-cel) | Arcellx | Phase 1 |
| DNTH103 | Dianthus Therapeutics | Phase 1b |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |